Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Multiple Myeloma
Interventions: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 34
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 21 more

Conditions: Colorectal Cancer, Colorectal Tumors, Colorectal Carcinoma, Colorectal Neoplasm
Interventions: Nivolumab, Trametinib, Ipilimumab, Regorafenib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Multiple Myeloma
Interventions: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 12
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more

Conditions: Red Blood Cell Transfusions
Interventions: Implementation strategies to increase use of transfusion recommendations; Other
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Palo Alto, California • Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: St Louis, Missouri • Gettysburg, Pennsylvania

Conditions: Remote Maintenance Training Program
Interventions: Wheelchair Maintenance Training; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: Not listed
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
Interventions: AdAPT-001, Checkpoint Inhibitor, Immune; Biological · Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Duarte, California • San Marcos, California • Santa Monica, California + 3 more

Conditions: Sickle Cell Disease
Interventions: Provider-level intervention, Patient-level intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 2 Years to 7 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Little Rock, Arkansas • Oakland, California • Wilmington, Delaware + 10 more

Conditions: Long QT Syndrome (LQTS) 2
Interventions: baseline lead-in, THRV-1268; Other · Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 6 more

Conditions: Medication Adherence, HIV
Interventions: dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg; Drug
Lead sponsor: Rhonda Brand; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumours
Interventions: CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Primary Ciliary Dyskinesia
Interventions: VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more

Conditions: Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions: BL-M17D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more

Conditions: Perimenopause
Interventions: Resistance Training Intervention; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions: denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more

Conditions: Bipolar Disorder
Interventions: Continuous Theta Burst Stimulation (cTBS), Intermittent Theta Burst Stimulation (iTBS); Device
Lead sponsor: Mary Phillips, MD MD (Cantab); Other
Eligibility: 18 Years to 35 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obsessive Compulsive Disorder
Interventions: CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 5 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Overactive Detrusor, Neurogenic Bladder
Interventions: Oxybutynin, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 16 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: Loma Linda, California • Orange, California • Aurora, Colorado + 7 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more

Conditions: Pharmacokinetics
Interventions: ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Polyneuropathies, Obesity, Bariatric Surgery Candidate
Interventions: High Intensity Interval Training (HIIT), Routine Exercise, Bariatric surgery; Other · Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 40 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Breast Cancer, Stage IV Breast Cancer, Breast Cancer, Breast Cancer Stage IV, Breast Cancer Metastatic, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Hormone-receptor-positive Breast Cancer
Interventions: Abemaciclib, Radiation Therapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lung Cancer, Non-small Cell Lung Cancer
Interventions: Patritumab, Erlotinib, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 20 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 26
States / cities: Glendale, Arizona • Duarte, California • La Verne, California + 23 more

Search by objective public record fields.

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Implementation of Red Blood Cell Transfusion Recommendations in the Pediatric Intensive Care Unit

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Wheelchair Maintenance Training Program

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Dissemination and Implementation of Stroke Prevention Looking at the Care Environment

Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Hemodynamics After Resistance Training

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Examining the Effect of EEG-guided Theta Burst Stimulation in Bipolar Disorder

Overlapping Neural Circuits in Pediatric OCD

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Study of ALKS 5461 in Healthy Volunteers

Effect of Exercise and Surgical Weight Loss on Polyneuropathy

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)